Swiss Researchers Struggle to Get Animal Experiments Approved

Scientists say that increasingly rigorous licensing procedures have complicated research efforts—and in some cases, stopped experiments completely.

Written byDiana Kwon
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

ABOVE: © ISTOCK, FILO

When Adriano Aguzzi, a neuropathologist at the University of Zurich, learned that the application to renew his lab’s license for mouse experiments was rejected in December, he was stunned. Aguzzi uses rodents to investigate prions—misfolded proteins that cause fatal neurodegenerative disorders such as Creutzfeldt-Jakob Disease—and for the last two decades, he has successfully received authorization to conduct studies that involve inoculating animals with prions and monitoring their vital signs as they develop disease. The latest license request was “the same application that has been renewed every three years,” he tells The Scientist.

Aguzzi is one of several scientists who say it has become increasingly difficult to get licenses for animal experiments in recent years. Switzerland has some of the strictest animal protection laws in the world, and as a result, the quantity of animals used in research has steadily declined over the years. Between 2008 and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies